Nautilus Biotechnology (NASDAQ:NAUT) CEO Buys $78,055.00 in Stock

Key Points

• Sujal Patel, CEO of Nautilus Biotechnology, purchased 116,500 shares at an average price of $0.67, increasing his ownership stake by 1.15% to over 10 million shares valued at approximately $6.87 million.
• Nautilus Biotechnology's stock price recently fell 4.4% to $0.67, with seasonal trading patterns indicating a 52-week low of $0.62 and a high of $3.09.
• Institutional investors now hold 50.71% of Nautilus Biotechnology's stock, with notable increases in stakes from several hedge funds like Presidio Capital Management and XTX Topco Ltd.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal M. Patel purchased 116,500 shares of the business's stock in a transaction that occurred on Friday, September 5th. The stock was bought at an average cost of $0.67 per share, with a total value of $78,055.00. Following the acquisition, the chief executive officer owned 10,258,221 shares in the company, valued at $6,873,008.07. This represents a 1.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Nautilus Biotechnology Price Performance

NASDAQ NAUT traded up $0.01 on Friday, hitting $0.72. The company had a trading volume of 280,945 shares, compared to its average volume of 238,015. The company has a market capitalization of $91.03 million, a PE ratio of -1.39 and a beta of 1.42. The company's fifty day moving average price is $0.73 and its 200-day moving average price is $0.79. Nautilus Biotechnology, Inc. has a 12-month low of $0.62 and a 12-month high of $3.09.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. On average, sell-side analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Barclays PLC lifted its position in Nautilus Biotechnology by 17.9% in the fourth quarter. Barclays PLC now owns 125,204 shares of the company's stock valued at $210,000 after buying an additional 19,030 shares during the last quarter. Jane Street Group LLC increased its stake in Nautilus Biotechnology by 188.1% during the fourth quarter. Jane Street Group LLC now owns 108,545 shares of the company's stock worth $182,000 after purchasing an additional 70,863 shares during the period. XTX Topco Ltd purchased a new stake in Nautilus Biotechnology during the first quarter worth about $31,000. Citadel Advisors LLC increased its stake in Nautilus Biotechnology by 171.4% during the fourth quarter. Citadel Advisors LLC now owns 220,220 shares of the company's stock worth $370,000 after purchasing an additional 139,081 shares during the period. Finally, Millennium Management LLC purchased a new stake in Nautilus Biotechnology during the fourth quarter worth about $63,000. Institutional investors and hedge funds own 50.71% of the company's stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.